RESUMO
BACKGROUND: Sarcoidosis-related pulmonary hypertension (SRPH) is an entity associated with significant morbidity and mortality irrespective of disease severity, while the pathogenic mechanisms remain poorly understood. METHODS: This cross-sectional study included consecutive patients with biopsy-proven sarcoidosis (n = 313) who were followed up in an outpatient setting from October 2002 through June 2010. All patients underwent clinical and cardiopulmonary evaluation, including cardiac MRI, to assess prevalence of SRPH and identify possible underlying pathophysiological mechanisms. RESULTS: By Doppler echocardiographic criteria, 37 (11.8 %) patients were found to have pulmonary arterial systolic pressure (PASP) >40 mmHg. Twelve of the 37 patients agreed to undergo right heart catheterization and SRPH was confirmed in nine patients. Compared to patients without SRPH, those with SRPH were significantly older and had greater lung function impairment; disease duration did not differ between patients with and without SRPH. Multiple logistic regression analysis showed that diffusing capacity for carbon monoxide (DLCO) and age were independent determinants of SRPH. Pulmonary fibrosis and left ventricular diastolic dysfunction due to cardiac sarcoidosis or other comorbidities accounted for SRPH in the majority of patients. In the nonpulmonary fibrosis group, DLCO ≤ 50.65 (% predicted) was associated with SRPH (sensitivity = 77.8 %, specificity = 72.2 %; p = 0.031, AUC = 0.759). CONCLUSION: In a large cohort of sarcoidosis patients, this study found a prevalence of SRPH of about 12 %. Pulmonary fibrosis and left ventricular diastolic dysfunction due to cardiac sarcoidosis or other comorbidities are frequent pathogenic mechanisms.
Assuntos
Pressão Arterial/fisiologia , Hipertensão Pulmonar/epidemiologia , Hipertensão Pulmonar/fisiopatologia , Sarcoidose Pulmonar/epidemiologia , Sarcoidose Pulmonar/fisiopatologia , Sístole/fisiologia , Adulto , Idoso , Biomarcadores/metabolismo , Monóxido de Carbono/metabolismo , Comorbidade , Estudos Transversais , Feminino , Hemodinâmica/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Prevalência , Capacidade de Difusão Pulmonar/fisiologia , Fibrose Pulmonar/fisiopatologia , Estudos Retrospectivos , Fatores de Risco , Sensibilidade e Especificidade , Disfunção Ventricular Esquerda/fisiopatologiaRESUMO
RATIONALE: Activin-A is up-regulated in various respiratory disorders. However, its precise role in pulmonary pathophysiology has not been adequately substantiated in vivo. OBJECTIVES: To investigate in vivo the consequences of dysregulated Activin-A expression in the lung and identify key Activin-A-induced processes that contribute to respiratory pathology. METHODS: Activin-A was ectopically expressed in murine lung, and functional, structural, and molecular alterations were extensively analyzed. The validity of Activin-A as a therapeutic target was demonstrated in animals overexpressing Activin-A or treated with intratracheal instillation of LPS. Relevancy to human pathology was substantiated by demonstrating high Activin-A levels in bronchoalveolar lavage (BAL) samples from patients with acute respiratory distress syndrome (ARDS). MEASUREMENTS AND MAIN RESULTS: Overexpression of Activin-A in mouse airways caused pulmonary pathology reminiscent of acute lung injury (ALI)/ARDS. Activin-A triggered a lasting inflammatory response characterized by acute alveolar cell death and hyaline membrane formation, sustained up-regulation of high-mobility group box 1, development of systemic hypercoagulant state, reduction of surfactant proteins SpC, SpB, and SpA, decline of lung compliance, transient fibrosis, and eventually emphysema. Therapeutic neutralization of Activin-A attenuated the ALI/ARDS-like pathology induced either by ectopic expression of Activin-A or by intratracheal instillation of LPS. In line with the similarity of the Activin-A-induced phenotype to human ARDS, selective up-regulation of Activin-A was found in BAL of patients with ARDS. CONCLUSIONS: Our studies demonstrate for the first time in vivo the pathogenic consequences of deregulated Activin-A expression in the lung, document novel aspects of Activin-A biology that provide mechanistic explanation for the observed phenotype, link Activin-A to ALI/ARDS pathophysiology, and provide the rationale for therapeutic targeting of Activin-A in these disorders.
Assuntos
Ativinas/metabolismo , Pulmão/metabolismo , Síndrome do Desconforto Respiratório/metabolismo , Receptores de Activinas Tipo II/uso terapêutico , Ativinas/análise , Lesão Pulmonar Aguda/metabolismo , Lesão Pulmonar Aguda/patologia , Animais , Líquido da Lavagem Broncoalveolar/química , Modelos Animais de Doenças , Feminino , Proteína HMGB1/metabolismo , Humanos , Pulmão/patologia , Camundongos , Camundongos Endogâmicos C57BL , Alvéolos Pulmonares/metabolismo , Alvéolos Pulmonares/patologia , Proteínas Recombinantes de Fusão/uso terapêutico , Síndrome do Desconforto Respiratório/tratamento farmacológico , Síndrome do Desconforto Respiratório/patologia , Mucosa Respiratória/metabolismo , Mucosa Respiratória/patologia , Regulação para CimaRESUMO
BACKGROUND: Cirrhosis is associated with several extrahepatic manifestations including portopulmonary hypertension (PPHT). Recent data suggest that endothelins (ETs) are related to the pathophysiology of PPHT. The study aimed to measure serum ET levels in hospitalized cirrhotic patients and to determine their association with PPHT and patient outcome. METHODS: Fifty-seven cirrhotic patients [43 males; median age 58 (28-87) years] underwent Doppler echocardiography. Patients with systolic pulmonary arterial pressure ≥40 mmHg and pulmonary acceleration time <100 ms were deemed to have PPHT. ET-1, 2, and 3 serum levels were measured with an ELISA assay. All-cause mortality was recorded over a median period of 24 months. RESULTS: Nine out of 57 patients (15.8%) had PPHT. Among various clinical variables, only autoimmune hepatitis was associated with PPHT (OR=11.5; 95% CI, 1.58-83.4; P=0.01). ET-1 levels [9.1 (1.6-20.7) vs 2.5 (1.4-9.2) pg/mL, P=0.02] and the ET-1/ET-3 ratio [4.73 (0.9-22.4) vs 1.6 (0.3-10.7), P=0.02] were significantly higher in patients with PPHT than in those without. ET-2 and ET-3 levels did not differ between the two groups. There was no difference in survival between the two groups, although ET-1 levels were associated with an adverse outcome in Cox regression analysis (HR=1.11; 95% CI, 1.02-1.22; P=0.02 per unit increase in ET-1). CONCLUSION: Our data suggest that ET-1 and the ET-1/ET-3 ratio are elevated in patients with PPHT and that ET-1 is associated with a poor outcome irrespective of PPHT.
Assuntos
Endotelinas/sangue , Hospitalização , Hipertensão Portal/sangue , Hipertensão Portal/etiologia , Hipertensão Pulmonar/sangue , Hipertensão Pulmonar/etiologia , Cirrose Hepática/sangue , Cirrose Hepática/complicações , Adulto , Idoso , Idoso de 80 Anos ou mais , Biomarcadores/sangue , Distribuição de Qui-Quadrado , Ecocardiografia Doppler em Cores , Ecocardiografia Doppler de Pulso , Endotelina-1/sangue , Endotelina-2/sangue , Endotelina-3/sangue , Ensaio de Imunoadsorção Enzimática , Feminino , Grécia , Humanos , Hipertensão Portal/diagnóstico , Hipertensão Portal/mortalidade , Hipertensão Pulmonar/diagnóstico , Hipertensão Pulmonar/mortalidade , Estimativa de Kaplan-Meier , Cirrose Hepática/diagnóstico , Cirrose Hepática/mortalidade , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Prognóstico , Modelos de Riscos Proporcionais , Medição de Risco , Fatores de Risco , Fatores de TempoRESUMO
Scleroderma sine scleroderma (ssSSc) is an occult form of systemic sclerosis that may cause diagnostic difficulties due to the absence of skin involvement. Delays in the diagnosis of ssSSc means lost opportunites to address and treat the often lethal involvement of internal organs such as the lungs and heart. In this systemic review we collected all published cases of ssSSc using EMBASE, MEDLINE, PubMed, and Web of Science from 1950 to present. Our purpose was to describe the range and frequency of the clinical manifestations of ssSSc. A total of 108 published cases of ssSSc were analyzed. Lung involvement was present in 66% of cases. Peripheral vascular system involvement was present in all patients whereas gastrointestinal manifestations were present in 82% of the cases. Overall the clinical presentation is subtle and heightened clinical awareness is required to facilitate prompt recognition and treatment.
Assuntos
Cardiopatias/diagnóstico , Pneumopatias/diagnóstico , Doenças Respiratórias/diagnóstico , Escleroderma Sistêmico/diagnóstico , Doenças Vasculares/diagnóstico , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Feminino , Cardiopatias/complicações , Humanos , Pneumopatias/complicações , Masculino , Pessoa de Meia-Idade , Doenças Respiratórias/complicações , Estudos Retrospectivos , Escleroderma Sistêmico/complicações , Doenças Vasculares/complicações , Adulto JovemRESUMO
Thoracic high-resolution computed tomography scans (HRCT) of 17 patients with inflammatory muscle disorders (IMD) and positive Jo1 antibodies were retrospectively reviewed regarding presence, extension, and distribution of pathological findings. Abnormal findings were found in 14 (82.3%) patients. The predominant CT abnormality was ground glass attenuation, which was present in seven patients (41.1%), having a bilateral and diffuse distribution. In general, lesions tended to appear in the lower lobes and more specifically in the lung bases. Interlobular septal thickening was found in six patients (35.3%); it was seen in the upper and lower lobes with peripheral distribution and bilateral localization in five out of six patients. Bronchiectases, reticular opacities, and honeycombing were found in six patients (35.3%). Air space consolidation was seen in about 17% of the patients. Lung involvement is a frequent feature of IMD patients with positive Jo1 antibodies and its most common radiological pattern is that of nonspecific interstitial pneumonia.
Assuntos
Autoanticorpos , Pneumopatias/diagnóstico por imagem , Miosite/complicações , Tomografia Computadorizada por Raios X/métodos , Feminino , Humanos , Doenças Pulmonares Intersticiais/diagnóstico por imagem , Masculino , Pessoa de Meia-Idade , Radiografia Torácica , Estudos Retrospectivos , SíndromeRESUMO
The chest wall consists of various structures that function in an integrated fashion to ventilate the lungs. Disorders affecting the bony structures or soft tissues of the chest wall may impose elastic loads by stiffening the chest wall and decreasing respiratory system compliance. These alterations increase the work of breathing and lead to hypoventilation and hypercapnia. Respiratory failure may occur acutely or after a variable period of time. This review focuses on the pathophysiology of respiratory function in specific diseases and disorders of the chest wall, and highlights pathogenic mechanisms of respiratory failure.
Assuntos
Doenças Torácicas/fisiopatologia , Parede Torácica/fisiopatologia , Tórax Fundido/fisiopatologia , Humanos , Hipoventilação/fisiopatologia , Cifose/fisiopatologia , Insuficiência Respiratória/fisiopatologia , Escoliose/fisiopatologia , Espondilite Anquilosante/fisiopatologiaRESUMO
OBJECTIVE: To define risk factors associated with pulmonary arterial hypertension (PAH) in a large cohort of patients with systemic sclerosis (SSc). METHODS: SSc patients undergoing screening for PAH by means of Doppler echocardiography were identified and their charts were retrospectively reviewed. In all patients, we recorded systolic pulmonary artery pressure along with pulmonary function testing, clinical, and laboratory data. PAH was defined as right ventricular systolic pressure equal or greater than 40 mm Hg. RESULTS: Of 114 SSc patients with echocardiographic measurements, PAH was found in 33 (29%) patients. In a multiple logistic regression analysis, the presence of pulmonary fibrosis on thoracic computed tomography (OR 6.78, CI 1.54 to 29.9), forced vital capacity less than 80% predicted (OR 3.03, CI 1.1 to 8.35), and duration of Raynaud's phenomenon preceding the onset of skin changes for at least 3 years (OR 5.75, CI 1.9 to 17.41) were found to be independent predictors of PAH. Age, disease duration, disease subtype, or autoantibodies were not associated with PAH in our patients. CONCLUSIONS: The present analysis identified pulmonary fibrosis and Raynaud's phenomenon preceding SSc skin manifestations by at least 3 years as risk factors for PAH in our scleroderma cohort. Screening for PAH in these high-risk patients may detect PAH at an earlier stage and guide decisions on therapeutic interventions.
Assuntos
Hipertensão Pulmonar/etiologia , Escleroderma Sistêmico/complicações , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Criança , Comorbidade , Ecocardiografia Doppler , Feminino , Grécia/epidemiologia , Humanos , Hipertensão Pulmonar/fisiopatologia , Masculino , Pessoa de Meia-Idade , Testes de Função Respiratória , Estudos Retrospectivos , Fatores de Risco , Escleroderma Sistêmico/fisiopatologiaRESUMO
BACKGROUND: In adults performing forceful expiratory maneuvers, the length of post-inspiratory pause prior to forced expiration may influence the subsequently measured peak expiratory flow (PEF) and increase its variability. We investigated the effects of two different lengths of breath-hold at total lung capacity (TLC) on the short-term reproducibility of PEF in healthy volunteers. METHODS: Forty-six healthy volunteers (age 34.6+/-8.5; 23 men) performed a series of maximal forceful expirations in two different test sessions, separated by approximately 2 weeks. In each test-session, PEF was measured with two different types of maneuvers. One maneuver (P) included a brief (<2s) post-inspiratory pause at TLC prior to forced expiration, whereas the second maneuver (NP) included no pause at TLC. The speed of inspiration to TLC was fast and similar for both maneuvers. In a given test session, all volunteers performed four efforts for each type of maneuver. The highest PEF for each maneuver was used for analysis. The Bland-Altman statistical analysis was used to determine inter-session reproducibility of PEF. RESULTS: Within-maneuver analysis of the between-test session reproducibility of PEF showed that neither maneuver systematically biased the measured PEF (mean difference 0.02L/s for the P and 0.17L/s for the NP maneuver). Inter-maneuver between-test session analysis similarly showed that neither maneuver introduced a systematic bias in the maximal PEF (mean difference ranged from -0.15 to -0.01L/s). The limits of agreement were comparable in all maneuver-pair analyses. CONCLUSIONS: Forceful expiratory maneuvers with or without a brief (<2s) pause at TLC produce comparable PEF values in test-retest sessions.
Assuntos
Pico do Fluxo Expiratório , Adulto , Feminino , Volume Expiratório Forçado , Humanos , Masculino , Reprodutibilidade dos Testes , Testes de Função Respiratória/métodos , Espirometria/métodos , Capacidade Pulmonar Total , Capacidade VitalRESUMO
Interstitial lung disease in patients with antisynthetase syndrome and no evidence of myositis is rare and may precede other disease manifestations. We report a patient who initially presented with symptoms primarily related to lung involvement. The diagnosis of the antisynthetase syndrome without myositis was made many months later when he developed a characteristic hand rash (mechanic's hands), which was confirmed by positive antibodies to Jo-1. With treatment, both the hand rash and the interstitial lung disease improved. Antisynthetase syndrome should be considered in patients presenting with interstitial lung disease with no evidence of myositis. Appropriate laboratory testing with measurement of specific autoantibodies may help in the early diagnosis and treatment of the syndrome.
Assuntos
Aminoacil-tRNA Sintetases/imunologia , Anticorpos Antinucleares/imunologia , Autoanticorpos/imunologia , Doenças Pulmonares Intersticiais/patologia , Miosite/patologia , Adulto , Anticorpos Antinucleares/sangue , Autoanticorpos/sangue , Humanos , Doenças Pulmonares Intersticiais/imunologia , Masculino , Miosite/imunologia , SíndromeRESUMO
PURPOSE: To test the hypothesis that ankylosing spondylitis (AS) alters the pattern of chest wall motion during speech production. METHOD: The pattern of chest wall motion during speech was measured with respiratory inductive plethysmography in 6 participants with advanced AS (5 men, 1 woman, age 45+/-8 years, Schober test 1.45+/-1.5 cm, Bath Ankylosing Spondylitis Functional Index [BASFI] score 6+/-1.7) and 6 healthy volunteers, matched for age and gender. Measurements were made with participants in the upright seated and upright standing body position. RESULTS: During reading in the seated and standing body positions, the rib cage wall volume displacements were smaller and abdominal wall volume displacements were larger in participants with AS than in healthy controls. There were no differences in the overall lung volume displacements recorded during the expiratory limb of reading in either body position. In the participants with AS, the rib cage remained near the end-expiratory level in both the seated and standing body position, differing from that for the control group. CONCLUSION: In individuals with advanced AS, the abdomen is the primary contributor to volume displacement. In the absence of speech impairment in participants with AS, the data show the capacity of the abdomen to compensate for the decreased compliance of the rib cage.
Assuntos
Movimento/fisiologia , Fala/fisiologia , Espondilite Anquilosante/patologia , Parede Torácica/fisiologia , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , RespiraçãoRESUMO
OBJECTIVES: The goal of this study was to assess the independent and collective diagnostic value of various modalities in cardiac sarcoidosis, delineate the role of cardiac magnetic resonance (CMR), and identify patients at risk. BACKGROUND: Cardiac sarcoidosis is associated with increased morbidity and mortality. CMR is a key modality in the evaluation of patients with cardiac symptoms, but the complementary role of CMR to conventional tests for the diagnosis of cardiac sarcoidosis is not fully defined. METHODS: Patients (N = 321) with biopsy-proven sarcoidosis underwent conventional cardiac testing and CMR with late gadolinium enhancement (LGE) and were followed up for primary (composite of all-cause mortality, sustained ventricular tachycardia [VT] episodes, or hospitalization for heart failure) and secondary (nonsustained VT episodes) endpoints. RESULTS: Cardiac sarcoidosis was diagnosed in 29.9% of patients according to the Heart Rhythm Society consensus criteria. CMR was the most sensitive and specific test (area under the curve: 0.984); it detected 44 patients with cardiac symptoms and/or electrocardiogram (ECG) abnormalities but normal echocardiogram, as well as 15 asymptomatic patients with normal baseline testing. Echocardiography added to cardiac history and ECG did not change sensitivity of the initial screening strategy (68.8% vs. 72.9%). Despite a high positive predictive value (83.9%), echocardiography had a low sensitivity (27.1%). During follow-up, 7.2% of patients reached the primary endpoint and another 3.4% reached the secondary endpoint. LGE was and independent predictor of primary endpoints (hazard ratio: 5.68; 95% CI: 1.74 to 18.49; p = 0.004). LGE, age, and baseline nonsustained VT were independent predictors of all events. In patients with cardiac symptoms and/or an abnormal ECG, CMR increased diagnostic accuracy and independently predicted primary endpoints (hazard ratio: 12.71; 95% confidence interval: 1.48 to 109.35; p = 0.021). CONCLUSIONS: Of all cardiac tests, CMR was the most valuable in the diagnosis and prognosis of cardiac sarcoidosis in a general sarcoidosis population. Echocardiography had an overall limited diagnostic value as a screening test, and an abnormal study, despite a high positive predictive value, may still need confirmation with CMR.
Assuntos
Cardiomiopatias/diagnóstico por imagem , Imagem Cinética por Ressonância Magnética , Miocárdio/patologia , Sarcoidose/diagnóstico por imagem , Adulto , Área Sob a Curva , Biópsia , Cardiomiopatias/complicações , Cardiomiopatias/mortalidade , Cardiomiopatias/patologia , Causas de Morte , Meios de Contraste/administração & dosagem , Ecocardiografia , Eletrocardiografia Ambulatorial , Feminino , Insuficiência Cardíaca/etiologia , Hospitalização , Humanos , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prognóstico , Curva ROC , Reprodutibilidade dos Testes , Fatores de Risco , Sarcoidose/complicações , Sarcoidose/mortalidade , Sarcoidose/patologia , Taquicardia Ventricular/etiologia , Fatores de TempoRESUMO
BACKGROUND/OBJECTIVES: To assess the effects of theophylline on pulmonary function in patients with chronic traumatic tetraplegia, we conducted a double-blind placebo-controlled crossover study in 10 patients. METHODS: The patients (age: 41 +/- 3 years; time from injury: 16 +/- 3 years; neurological levels: C3 to C7-T1) were randomized to receive oral theophylline or placebo for 6 weeks. After 2 months of washout, the patients received the medication not taken in the first trial for an additional 6 weeks. We measured lung volumes, expiratory flow rates, maximal inspiratory pressure (MIP), and maximal expiratory pressure (MEP) at both baseline and at the end of each treatment arm. Theophylline blood serum assays were measured during the first week of the treatment and on the day of respiratory measurements. RESULTS: Mean theophylline level on the day of treatment completion was 12.6 +/- 1.4 microg/mL. In analyzing the data from the group of 10 patients, the percent changes from baseline in total lung capacity, forced vital capacity, forced expiratory volume at 1 second, MIP, and MEP did not differ significantly between the two treatment arms (P > 0.05 in all). CONCLUSION: These data show that in this small group of 10 subjects with chronic tetraplegia, administration of oral theophylline did not improve pulmonary function.
Assuntos
Broncodilatadores/farmacologia , Pulmão/efeitos dos fármacos , Pulmão/fisiopatologia , Quadriplegia/fisiopatologia , Teofilina/farmacologia , Adulto , Estudos Cross-Over , Método Duplo-Cego , Expiração/efeitos dos fármacos , Expiração/fisiologia , Feminino , Volume Expiratório Forçado/efeitos dos fármacos , Volume Expiratório Forçado/fisiologia , Humanos , Inalação/efeitos dos fármacos , Inalação/fisiologia , Masculino , Quadriplegia/complicações , Mecânica Respiratória/efeitos dos fármacos , Mecânica Respiratória/fisiologia , Capacidade Pulmonar Total/efeitos dos fármacos , Capacidade Pulmonar Total/fisiologia , Capacidade Vital/efeitos dos fármacos , Capacidade Vital/fisiologiaRESUMO
BACKGROUND: The duration of postinspiratory pause prior to forced expiration may significantly influence the peak expiratory flow (PEF) measured during maximal forceful expirations. In comparison with maneuvers without a postinspiratory pause, maneuvers with 4 to 6-s pause at total lung capacity (TLC) result in decreased PEF values. The extent to which brief pauses (< 2 s) similarly affect PEF values is unknown. METHODS: Thirty-six healthy volunteers (mean [+/-SD] age, 35 +/- 8 years; 18 men) performed a series of maximal forceful expirations with two different types of maneuvers. One maneuver (NP) included no inspiratory pause at TLC prior to forceful expiration, whereas the second (P) included a brief pause (< or = 2 s). The speed of inhalation to TLC was rapid and similar for both maneuvers. The highest PEF for each maneuver was used for analysis. RESULTS: The maximal PEF did not differ (p > 0.05) between the P and NP maneuvers (7.78 +/- 1.45 vs 7.83 +/- 1.45 L/s, respectively). Comparison of the intermaneuver differences showed a bias of 0.05 L/s and 95% confidence interval in the range of -0.9 to 1.0 L/s. CONCLUSIONS: Forceful expiratory maneuvers with or without postinspiratory pauses of < or = 2 s produce identical maximal PEF values and, therefore, can be used interchangeably for the spirometric measurement of PEF in healthy subjects.
Assuntos
Pico do Fluxo Expiratório/fisiologia , Adulto , Feminino , Humanos , Medidas de Volume Pulmonar , Masculino , Músculos Respiratórios/fisiologia , EspirometriaRESUMO
OBJECTIVE: To examine the extent of cardiac muscle and sternocleidomastoid muscle (SCM) involvement detected by MRI measurement of T2 relaxation time in patients with Duchenne muscular dystrophy (DMD) and no cardiorespiratory symptoms. DESIGN: Prospective controlled study. SETTING: Teaching referral hospital and university hospital. SUBJECTS: Seventeen patients with DMD (age range, 7 to 25 years) and 17 age-matched control subjects. All patients were free of cardiac or respiratory complaints and had normal ECG, echocardiograph, and Holter monitor examination findings. METHODS: We assessed respiratory function by means of standard pulmonary function testing. MRI measurements included the T2 relaxation time of the myocardium and the SCM in patients and control subjects. RESULTS: The FVC and FEV1 values were lower in patients with DMD than in age-matched control subjects, whereas the FEV1/FVC ratio was normal in all subjects. Patients with DMD had lower T2 relaxation time of the heart (37.8 +/- 6.1 ms vs 58.1 +/- 7.1 ms, p < 0.001) and lower T2 relaxation time of the right SCM (24.5 +/- 2.6 ms vs 42.2 +/- 1.3 ms, p < 0.001) and left SCM (23.2 +/- 3.2 ms vs 42.2 +/- 1.6 ms, p < 0.001), compared to control subjects (+/- SD). In children (< 12 years of age), the T2 of the SCM was lower than that of the control subjects, but T2 of the heart did not differ between the two groups. In the patient group, T2 relaxation time of the heart decreased with age (r = - 0.80, p < 0.001). In patients with FVC < 80% of predicted, the T2 values of the heart were lower than the T2 values of patients with FVC > or = 80% of predicted (35.6 +/- 5.8 ms vs 41.8 +/- 4.6 ms, p < 0.05). CONCLUSIONS: MRI measurements of the T2 relaxation time in the myocardium and SCM of patients with DMD and no cardiorespiratory symptoms are abnormal, indicating altered tissue composition. These measurements may prove a clinically useful test for monitoring cardiac and respiratory muscle involvement in these patients.
Assuntos
Músculo Esquelético/patologia , Distrofia Muscular de Duchenne/patologia , Miocárdio/patologia , Adolescente , Adulto , Criança , Estudos Transversais , Volume Expiratório Forçado , Humanos , Imageamento por Ressonância Magnética , Masculino , Distrofia Muscular de Duchenne/fisiopatologia , Estudos Prospectivos , Testes de Função Respiratória , Capacidade VitalRESUMO
Respiratory dysfunction frequently occurs in patients with advanced multiple sclerosis (MS), and may manifest as acute or chronic respiratory failure, disordered control of breathing, respiratory muscle weakness, sleep disordered breathing, or neurogenic pulmonary edema. The underlying pathophysiology is related to demyelinating plaques involving the brain stem or spinal cord. Respiratory complications such as aspiration, lung infections and respiratory failure are typically seen in patients with long-standing MS. Acute respiratory failure is uncommon and due to newly appearing demyelinating plaques extensively involving areas of the brain stem or spinal cord. Early recognition of MS patients at risk for respiratory complications allows for the timely implementation of care and measures to decrease disease associated morbidity and mortality.
Assuntos
Esclerose Múltipla/fisiopatologia , Humanos , Esclerose Múltipla/patologia , Insuficiência Respiratória/patologia , Insuficiência Respiratória/fisiopatologia , Músculos Respiratórios/fisiopatologiaRESUMO
OBJECTIVES: To describe the evolution of valve involvement and myocardial dysfunction over time in patients with systemic lupus erythematosus (SLE) with or without antiphospholipid antibodies (aPL) and/or antiphospholipid syndrome (APS). METHODS: From an initial cohort of 150 patients assessed by transthoracic echocardiography 10 years ago, 17 patients with primary APS (PAPS), 23 with SLE-associated APS (SLE/APS), 19 with SLE positive for aPL without APS, and 23 with SLE negative for aPL were re-evaluated in the present echocardiography study. RESULTS: Valvulopathy was detected in 65% of PAPS and 62% of SLE patients with or without aPL. Disease duration [odds ratio (OR), 1.63; 95% confidence interval (CI), 1.13-2.36; p = 0.009 for every 5 years of increase] and presence of SLE/APS (OR, 3.51; 95% CI, 1.27-9.67; p = 0.015) were the only factors associated with the progression of valvular disease in univariate and multivariate analyses. Left ventricular diastolic dysfunction similarly progressed over time, with deceleration time (DT) and isovolumic relaxation time (IVRT) being equally prolonged in each of the four groups (p < 0.05). Right ventricular DT was significantly prolonged in each of the three SLE patient groups (p < 0.001), whereas IVRT increased only in SLE/APS patients (p = 0.040). CONCLUSIONS: Among patients with APS and SLE (with or without aPL), SLE/APS and disease duration were independent factors for valvular disease progression in the present 10-year follow-up echocardiography study. Anticoagulation did not arrest valvular disease progression. Ventricular diastolic dysfunction, primarily of the left ventricle, also progressed over the 10-year period.